Morepen Laboratories · NSE: MOREPENLAB · BSE: 500288
Q2 FY25 results · Jul–Sep 2024
Morepen Laboratories reported revenue from operations of ₹437.73 crore (up 3.8% from Q2 FY24) and net profit of ₹34.85 crore (up 63.9% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 437.73 | 421.77 | +3.8% | 455.22 | −3.8% |
| Other income | 4.99 | 3.24 | +54.1% | 3.43 | +45.6% |
| Total income | 442.71 | 425.01 | +4.2% | 458.64 | −3.5% |
| Profit before tax | 46.02 | 28.68 | +60.5% | 48.17 | −4.5% |
| Net profit for the period | 34.85 | 21.26 | +63.9% | 36.17 | −3.6% |
| EPS, basic (₹) | 0.65 | 0.42 | +54.8% | 0.71 | −8.5% |
| Net margin (%) | 8.0 | 5.0 | 7.9 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 383.70 | 381.26 | +0.6% | 385.64 | −0.5% |
| Other income | 4.63 | 2.84 | +63.2% | 3.07 | +50.8% |
| Total income | 388.33 | 384.10 | +1.1% | 388.72 | −0.1% |
| Profit before tax | 42.86 | 27.33 | +56.8% | 47.05 | −8.9% |
| Net profit for the period | 31.93 | 19.92 | +60.2% | 35.05 | −8.9% |
| EPS, basic (₹) | 0.60 | 0.39 | +53.8% | 0.69 | −13.0% |
| Net margin (%) | 8.3 | 5.2 | 9.1 |
Consolidated
- Filed with BSE
- 11 Nov 2024, 18:42 IST
- Board meeting
- 11 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2024, 18:42 IST
- Board meeting
- 11 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE